Navigation Links
Latest advances in interventional cardiology for congenital heart disease presented
Date:7/18/2008

Distinguished medical experts in the burgeoning field of interventional therapies for congenital and structural heart disease will gather in Las Vegas July 20-23 for the Pediatric & Adult Interventional Cardiac Symposium (PICS/AICS). Specialists from Rush University Medical Center in Chicago will perform live cases utilizing advance technologies during the course of symposium.

On Monday, July 21st, Dr. Ziyad M. Hijazi, director of the Rush Center for Congenital and Structural Heart Disease, will perform closure of an atrial septal defect (ASD) and patent ductus arteriosus closure. Hijazi is the course director and a founding member of PICS/AICS. He recently became the 31st president of the Society for Cardiovascular Angiography and Interventions (SCAI).

Several specialists from Rush will moderate or lead sessions, including a workshop about ASD involving Hijazi, Michel Ilbawi, chief of Pediatric Cardiac Surgery, and Zahid Amin, interventional cardiologist; a discussion about catheterizing critically ill infants led by Ilbawi, a breakout session about adult structural heart disease moderated by Dr. Cliff Kavinsky, interventional cardiologist; and a program on closure of ventricular septal defects by Amin.

In addition, specialists from Rush will present numerous studies, including information on the use of the Hemcon1 bandage to shorten the duration of bed rest following cardiac catheterization procedures, the safety of patent foramen ovale closure in elderly patients, and maternal and fetal outcomes following transcatheter device closure of ASD.

PICS/AICS 2008 is the most comprehensive symposium worldwide in the field of interventional therapies for congenital and structural heart disease in children and adults. The four-day conference brings together a select international faculty who provide demonstration, live operations and present the latest breakthroughs in their field. The symposium attracts more than 800 interventional cardiologists from more than 60 countries.

Hijazi is a pioneer in the non surgical repair of congenital heart defects. In addition to being widely published in his area of expertise, he has led groundbreaking national clinical trials of novel transcatheter closure devices for the treatment of ASD, ventricular septal defects, patent ductus ateriosys and patent foramen ovale. As a result of his research, the FDA approved the first ASD closure device for use in children in 2001.

Currently, Hijazi is evaluating percutaneous valve implantation for patients with defective pulmonary valves. In 2005, Hijazi became the first person in the United States to perform this innovative procedure.


'/>"/>

Contact: Kim Waterman
kimberly_waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related biology news :

1. Iowa State professors genome research published in the latest issue of Science
2. Latest Integrated Microbial Genomes data management system update release
3. Leading researchers and experts gather to discuss latest advancements in drug discovery
4. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
5. Cardiologists and heart surgeons meet for Controversies and Advances conference
6. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
7. Genetic Engineering & Biotechnology News reports on advances in miRNA
8. Prototype terahertz imager promises biochem advances
9. Science expands Science Signaling, featuring research related to medical advances, and more
10. Analysis of RNA role in spreading disease advances study of damaging plant infections
11. Iowa State-ConocoPhillips collaboration advances 26 research projects in first year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology: